Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.98 EUR | -1.28% | -2.20% | -3.39% |
May. 13 | Eurofins Scientific to Expand US Battery Materials Testing Capabilities | MT |
May. 13 | Eurofins Scientific expands capacity in the USA | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company is in debt and has limited leeway for investment
- The firm trades with high earnings multiples: 27.75 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.39% | 11.93B | A- | ||
+17.74% | 83.47B | C+ | ||
-29.66% | 69.72B | B- | ||
-0.85% | 26.5B | C+ | ||
+3.06% | 17.69B | A- | ||
-12.16% | 16.83B | B | ||
+2.47% | 15.7B | A- | ||
+74.82% | 13.45B | C- | ||
+73.52% | 12.81B | C+ | ||
+0.76% | 12.69B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERF Stock
- Ratings Eurofins Scientific SE